Skip to content
10-Q

Quarterly Report

NORTHWEST BIOTHERAPEUTICS INC NWBO

0001410578-24-001879

← back to feed
Filed
Nov 12, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 8, 2024 1.3B sh
Long Term Debt Q3 2024 · Sep 30, 2024 $53.25M
Long Term Debt Q3 2024 · Dec 31, 2023 $40.79M
Cash And Equivalents Q3 2024 · Sep 30, 2024 $2.94M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $2.13M
Current Liabilities Q3 2024 · Sep 30, 2024 $59.56M
Current Liabilities Q3 2024 · Dec 31, 2023 $45.2M
Total Liabilities Q3 2024 · Sep 30, 2024 $93.56M
Total Liabilities Q3 2024 · Dec 31, 2023 $74.92M
Current Assets Q3 2024 · Sep 30, 2024 $5.19M
Current Assets Q3 2024 · Dec 31, 2023 $4.13M
Total Assets Q3 2024 · Sep 30, 2024 $29.32M
Total Assets Q3 2024 · Dec 31, 2023 $27.87M
Shares Diluted Q3 2024 · Sep 30, 2023 1.13M sh
Shares Diluted Q3 2024 · Sep 30, 2023 1.11M sh
Capex Q3 2024 · Sep 30, 2023 $3.02M
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$36.68M
Stockholders Equity restated Q3 2024 · Sep 30, 2023 −$70.06M
Stockholders Equity Q3 2024 · Jun 30, 2023 −$61.03M
Stockholders Equity Q3 2024 · Dec 31, 2022 −$128.1M
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.02
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$0.05
Eps Basic Q3 2024 · Sep 30, 2023 −$0.02
Eps Basic restated Q3 2024 · Sep 30, 2023 −$0.05
Sga Expense Q3 2024 · Sep 30, 2023 $7.03M
Sga Expense Q3 2024 · Sep 30, 2023 $21.58M
Rd Expense Q3 2024 · Sep 30, 2023 $7.2M
Rd Expense Q3 2024 · Sep 30, 2023 $20.28M
Net Income restated Q3 2024 · Sep 30, 2023 −$23.52M
Net Income restated Q3 2024 · Sep 30, 2023 −$48.62M
Operating Income Q3 2024 · Sep 30, 2023 −$13.83M
Operating Income Q3 2024 · Sep 30, 2023 −$40.37M
Revenue Q3 2024 · Sep 30, 2023 $406K
Revenue Q3 2024 · Sep 30, 2023 $1.49M